Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma
Explore how early-relapse multiple myeloma treatment shifts toward CAR T and bispecifics, weighing high-risk biology, kidney issues, logistics, and infection safety.
Experts weigh how to sequence myeloma therapies, highlighting where antibody-drug conjugates like belantamab fit when CAR-T or bispecific options aren’t feasible.
Early myeloma referral to academic centers helps patients access trials, avoid therapy pitfalls, and stay eligible for earlier CAR-T and bispecifics.
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
5